Sinfonia Biotherapeutics

Sweden
Huddinge, Stockholm, Sweden

Company profile

Sinfonia Biotherapeutics company profile

Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined orphan neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s and Parkinson’s disorders. Just as cancer is composed of many different subtypes, they know dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, they are developing breakthrough biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are known.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2000-01-01

Headquarters

Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Last funding
Grant / $80,865 / 2018-12-01
Investors
1
Founders
1
Articles
2

Founders and investors

Founders

Lars Wahlberg

Investors

EISMEA